Acute Erythroid Leukemia: Symptoms, Diagnosis, and Treatment

Acute erythroid leukemia (AEL) is a rare and aggressive blood cancer in which the bone marrow becomes overwhelmed by immature red blood cell precursors instead of producing healthy blood cells. It accounts for a small fraction of all acute myeloid leukemia (AML) cases, tends to strike older adults, and carries a notably poor prognosis compared to most other AML subtypes. Because of its rarity, AEL has historically been difficult to study, and its very definition has shifted repeatedly over the past century, making it one of the more confusing diagnoses in hematology.

A Disease That Keeps Getting Renamed

Few cancers have undergone as many classification changes as AEL. Since the early twentieth century, doctors have called it erythroleukemia, erythremic myelosis, AML-M6, and pure erythroid leukemia, among other names.¹ The most recent shake-up came in 2022, when two major classification systems were published almost simultaneously. The World Health Organization’s fifth edition settled on the term “acute erythroid leukemia” and defined it as a bone marrow biopsy in which at least 30% of cells are proerythroblasts and erythroid precursors make up at least 80% of all marrow cells. Meanwhile, the International Consensus Classification took a different approach, folding what had been called pure erythroid leukemia into a broader category of AML with mutated TP53.² This dual-system situation means that the diagnosis you receive can depend in part on which classification your pathologist follows, a source of real confusion for patients and clinicians alike.

Who Develops AEL

AEL overwhelmingly affects older adults. In a large U.S. study of nearly a thousand patients drawn from the national SEER cancer registry, the median age at diagnosis was 68 years. About 62% of patients were male.³ Interestingly, that same study found the age distribution was not a simple bell curve. It showed multiple peaks, suggesting there may be biologically distinct groups of patients who develop the disease at different ages, potentially including a smaller cohort of younger adults or even rare pediatric cases.

While most AEL arises without an obvious trigger, some cases develop after prior cancer treatment. Chemotherapy and radiation therapy, particularly alkylating agents, are known to damage bone marrow DNA in ways that can set the stage for secondary leukemia years later. Case reports have described AEL developing after treatment for multiple myeloma, including in patients who underwent high-dose chemotherapy followed by stem cell transplantation.⁴ This therapy-related form of AEL is an added risk that oncologists weigh when planning intensive treatments for other blood cancers.

Symptoms and How They Present

AEL does not announce itself with a unique set of symptoms. Because the leukemic cells crowd out normal blood-producing cells in the bone marrow, patients typically show up with the consequences of having too few healthy blood cells. Severe anemia is usually the dominant problem, leading to profound fatigue, pallor, shortness of breath on exertion, and dizziness. Low platelet counts cause easy bruising and bleeding, whether from the gums, the nose, or into the skin as small red or purple spots. Low white blood cell counts leave patients vulnerable to infections that are difficult to shake, including fevers without an obvious source.

Some patients also develop what doctors call extramedullary involvement, meaning the leukemia has spread outside the bone marrow. This can occasionally cause an enlarged spleen or liver, or rarely, skin nodules. But for most patients, the initial picture is dominated by severe, worsening anemia that does not respond to the usual treatments like iron or vitamin supplements, prompting the blood tests and bone marrow biopsy that lead to a diagnosis.

How AEL Is Diagnosed

Diagnosis starts with standard blood work, which usually reveals a dramatically low hemoglobin level along with reduced platelets and abnormal white cell counts. These findings are not specific to AEL, so the critical next step is a bone marrow biopsy. Under the microscope, the marrow in AEL looks strikingly abnormal. In one published case, the aspirate was hypercellular and composed of roughly 85% erythroid precursors with prominent dysplasia, including nuclear budding, cells with multiple nuclei, and an abnormally large cell size. Proerythroblasts, the most immature form, made up about 43% of the erythroid population, while the myeloid and megakaryocytic cells looked relatively normal.⁵ A special stain called Periodic Acid-Schiff (PAS) often shows a coarse, blocky pattern in the erythroblasts, which helps pathologists distinguish them from normal red cell precursors.

Immunophenotyping

Because the immature erythroid cells in AEL can sometimes look confusingly similar to myeloid blasts or even reactive (non-cancerous) erythroid expansions, pathologists rely on flow cytometry to pin down the diagnosis. Flow cytometry uses antibodies tagged with fluorescent markers to identify which proteins sit on the surface of the abnormal cells. In AEL, the leukemic erythroid cells consistently express two markers: CD36 and CD71. CD117 is expressed in most cases, though the intensity varies. The cells are typically negative for myeloperoxidase, which helps rule out a standard myeloid blast population.⁶

Several abnormal marker patterns help separate AEL from a reactive marrow that simply has a lot of red cell production. In one study, about 87% of AEL cases showed decreased or absent CD38 expression, whereas reactive early erythroid precursors displayed bright CD38, a statistically robust difference. Aberrant expression of CD7 and CD13, markers not normally found on red cell precursors, appeared only in the leukemic cases. Another useful clue is CD34: normal bone marrow usually contains a small subset of CD34-positive early erythroid precursors, but in AEL the malignant proerythroblasts are consistently CD34-negative.⁷ Mass cytometry, a newer and higher-resolution technology, has added further detail by revealing aberrant erythroid marker expression even in the very earliest stem cell compartment, suggesting the disease begins its hijacking early in blood cell development.⁸

Why Misdiagnosis Happens

AEL is one of the easier leukemias to misclassify. The presence of CD13 in roughly two-thirds of cases and CD33 in a similar proportion can mislead pathologists into thinking they are looking at a standard myeloid blast population, especially if they do not specifically look for erythroid markers like CD36 and CD71.⁶ The fact that classification criteria have changed repeatedly over the decades only compounds the problem. Older pathology reports may use the FAB system’s M6 designation, which grouped together subtypes that the WHO and ICC now handle quite differently. If you are reviewing older medical records or seeking a second opinion, it is worth confirming which classification system was used.

The Genetic Landscape

AEL has one of the most distinctive genetic signatures of any leukemia subtype: near-universal loss of functional TP53, the gene that encodes the p53 tumor-suppressor protein. In one study that tested 21 AEL cases, every single patient had at least one TP53 mutation, and all 20 who underwent standard chromosome analysis showed complex karyotypes, meaning their leukemia cells carried numerous large-scale chromosomal rearrangements.⁹ Most of these mutations are biallelic, meaning both copies of the gene are knocked out. This is significant because p53 acts as a critical brake on cell growth; when both copies fail, the cell loses one of its most important safeguards against uncontrolled proliferation. The complex karyotype frequently includes deletions of chromosomes 5q and 7q, which are also common in therapy-related myeloid cancers.¹⁰

This genetic profile explains why AEL is so difficult to treat. TP53-mutated leukemias across the board respond poorly to conventional chemotherapy, and the complex karyotype is itself an independent marker of poor prognosis. It also explains the overlap between AEL and the ICC’s decision to fold the disease into a broader TP53-mutated AML category: from a genetic standpoint, the TP53 mutation is arguably the defining event, with the erythroid phenotype being one of several possible downstream outcomes.

How AEL Develops at the Cellular Level

Recent laboratory work has shed light on how the combination of TP53 loss and other genetic hits specifically steers leukemia toward an erythroid phenotype rather than a generic myeloid one. In a 2024 study, researchers created a mouse model by depleting the mouse equivalent of TP53 and overexpressing a gene called ERG in bone marrow cells. This combination produced AEL with 100% penetrance within two months of transplantation, whereas ERG overexpression in cells with intact TP53 did not cause disease.¹¹ The mechanism involves ERG blocking a key regulator of red blood cell maturation called KLF1, which prevents immature erythroid cells from maturing normally. Meanwhile, the loss of TP53 removes the usual proliferation brake, allowing those stuck-in-immaturity cells to multiply unchecked. This two-hit model, one that blocks differentiation and one that enables proliferation, mirrors how other leukemias develop but is now understood with notable specificity in AEL.

Treatment Options

Treatment for AEL generally falls into three categories: intensive chemotherapy, lower-intensity drug regimens, and stem cell transplantation. The choice depends on a patient’s age, overall fitness, and how their bone marrow responds to initial therapy.

Intensive Chemotherapy

Standard AML induction chemotherapy, typically a combination of an anthracycline and cytarabine, has historically been the first-line approach for patients fit enough to tolerate it. However, AEL responds poorly compared to other AML subtypes. A multinational retrospective study of 217 patients found that overall survival with intensive chemotherapy was about 10.5 months, only modestly different from lower-intensity approaches.¹² For younger patients in good health who achieve a complete remission, intensive chemotherapy can serve as a bridge to stem cell transplantation, which remains the only treatment with a realistic chance of long-term disease control.

Hypomethylating Agents

For patients who are too old or too frail for intensive chemotherapy, hypomethylating agents such as azacitidine offer a tolerable alternative. In a small case series of five AEL patients (median age 70) treated with azacitidine, four achieved transfusion independence, meaning they no longer needed regular blood transfusions, two reached complete remission, and one had a partial remission. The median survival of the group was 20 months.¹³ In the larger multinational study, patients with high-risk chromosomal abnormalities who received a hypomethylating agent as first-line therapy actually lived longer than those given intensive chemotherapy (about 13.3 versus 7.5 months).¹² This counterintuitive finding suggests that for the high-risk genetic profile typical of AEL, going gentler with therapy can sometimes outperform the aggressive approach, likely because the patients tolerate more treatment cycles without being derailed by side effects.

Stem Cell Transplantation

Allogeneic stem cell transplantation, in which a patient receives bone marrow from a donor, is the most effective therapy for AEL when it is feasible. One study reported a median survival of 89 months from transplant, compared to just 5 months for patients who did not undergo the procedure.¹⁴ That survival gap is enormous, but the comparison comes with caveats: patients selected for transplant are generally younger, fitter, and more likely to have achieved a remission first. Transplantation also carries serious risks, including graft-versus-host disease, which occurred in about half of patients in that same study for acute forms and a third for chronic forms. For older patients or those who never achieve remission, transplant is often not an option.

Living with Treatment Side Effects

Because AEL patients frequently require large numbers of blood transfusions, both before and during treatment, iron overload is a significant concern. Each unit of transfused red blood cells delivers a load of iron that the body has no efficient way to excrete. Over time, excess iron accumulates in the liver, heart, and endocrine organs, potentially causing organ damage. Iron overload has been documented in about 75% of leukemia patients whose ferritin levels climbed above 1,000 ng/mL, with liver and heart imaging confirming the deposits. Iron-chelation therapy, which uses medications to bind excess iron so the body can eliminate it, has been used successfully in these patients.¹⁵

For patients who achieve remission and are well enough afterward, weekly therapeutic phlebotomy, essentially removing blood at regular intervals, is another way to bring iron levels down. In a small study of leukemia survivors with significant iron overload, weekly phlebotomy sessions gradually resolved the abnormalities associated with excess iron storage.¹⁶ Because iron overload tends to be more pronounced in AML patients than in other leukemia types, early attention to ferritin levels and timely intervention can make a meaningful difference in long-term organ health.¹⁷

Beyond iron, the broader quality-of-life picture for AML patients who are not candidates for intensive chemotherapy is concerning. Studies using validated questionnaires have shown that these patients score poorly on fatigue and overall health status at baseline, and that low physical functioning and high fatigue scores independently predict shorter survival. There is a silver lining: patients who respond to treatment, including lower-intensity regimens, tend to see meaningful improvements in physical functioning, cognitive functioning, and fatigue scores over time.¹⁸ This reinforces the idea that even when cure is unlikely, effective treatment can genuinely improve how a patient feels day to day.

Emerging Research Directions

Given how poorly AEL responds to existing therapies, researchers are actively searching for new targets. The same 2024 study that built the TP53/ERG mouse model also identified a potential vulnerability: an enzyme called HDAC7. When HDAC7 was inhibited, immature erythroid leukemia cells were pushed toward maturation, essentially restarting the differentiation program that ERG had blocked. The researchers showed that HDAC7 and ERG physically interact in leukemia cells and that disrupting this interaction allowed erythroid gene programs to resume.¹¹ HDAC inhibitors already exist as approved drugs for other cancers, so repurposing them for AEL is plausible, though clinical trials specific to AEL have not yet been reported.

On the diagnostic side, single-cell transcriptomic mapping, a technology that reads gene activity in individual cells rather than in bulk tissue, is beginning to reshape how researchers understand AEL’s place in the broader AML landscape. A large-scale analysis mapping over 1.2 million single-cell transcriptomes across hundreds of AML and AEL samples revealed that TP53 mutations are specifically linked to erythroid priming, meaning that among all the ways a leukemia cell can go wrong in its development, TP53 loss steers it toward the red blood cell lineage more than other mutation types do. This helps explain why AEL looks and behaves so differently from other AML subtypes despite sharing some of the same genetic hits.

What Patients and Families Should Know About Prognosis

AEL is among the least favorable AML subtypes. In the SEER-based U.S. study, roughly 62% of patients received chemotherapy, meaning a substantial proportion were never treated with disease-directed therapy at all, likely reflecting the advanced age and frailty of many patients at diagnosis.³ Among those who are treated, the multinational study found median survival in the range of 10 to 14 months depending on the therapy used.¹² The major exception is patients who can get to transplant, where median survival stretches to years rather than months.

For a patient or family facing this diagnosis, a few practical points are worth keeping in mind. First, because AEL is so rare, seeking care at a center with experience in aggressive AML subtypes matters. Second, getting clarity on which classification system was used for the diagnosis, WHO versus ICC, can affect treatment decisions and eligibility for clinical trials. Third, the question of transplant eligibility should be raised early, since the window for that option requires achieving at least a partial remission. And finally, because the standard treatments are limited in their effectiveness, asking about clinical trials is especially reasonable for AEL. The identification of potential targets like HDAC7 and the growing understanding of how TP53 loss drives this disease suggest that the treatment landscape, while bleak today, is not static.

1
PubMed. A History and Current Understanding of Acute Erythroid Leukemia
2
PubMed Central. Pure (acute) erythroid leukemia: morphology, immunophenotype, cytogenetics, mutations, treatment details, and survival data among 41 Mayo Clinic cases
3
PubMed Central. Survival after Pure (Acute) Erythroid Leukemia in the United States: A SEER-Based Study
4
PubMed Central. Acute Erythroid Leukemia Post-Chemo-Radiotherapy and Autologous Stem Cell Transplantation Due to Multiple Myeloma: Tracing the Paths to Leukemic Transformation
5
International Journal of Bone Marrow Research. Pure Erythroid Leukemia: The Sole Acute Erythroid Leukemia
6
PubMed Central. Pure (acute) erythroid leukemia: morphology, immunophenotype, cytogenetics, mutations, treatment details, and survival data among 41 Mayo Clinic cases
7
PubMed. Flow cytometry immunophenotypic features of pure erythroid leukemia and the distinction from reactive erythroid precursors
8
PubMed. Immunophenotypical profiling of myeloid neoplasms with erythroid predominance using mass cytometry (CyTOF)
9
PubMed Central. Pure erythroid leukemia is characterized by biallelic TP53 inactivation and abnormal p53 expression patterns in de novo and secondary cases
10
International Journal of Molecular Sciences. Acute Erythroid Leukemia: From Molecular Biology to Clinical Outcomes
11
PubMed Central. HDAC7 is a potential therapeutic target in acute erythroid leukemia
12
PubMed Central. Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study
13
PubMed Central. Treatment of acute erythroleukemia with Azacitidine: A case series
14
Biology of Blood and Marrow Transplantation. Clinical Outcomes in Acute Erythroid Leukemia Using the 2008 World Health Organization Definition
15
Journal of Pediatric Hematology/Oncology. Biochemical, Radiologic, Ultrastructural, and Genetic Evaluation of Iron Overload in Acute Leukemia and Iron-chelation Therapy
16
PubMed. Transfusion iron overload in adults with acute leukemia: manifestations and therapy
17
PubMed Central. Iron overload during the treatment of acute leukemia: pretransplant transfusion experience
18
ClinicoEconomics and Outcomes Research. Health-related quality of life in acute myeloid leukemia patients not eligible for intensive chemotherapy: results of a systematic literature review